Caixin
Jan 20, 2023 02:50 AM
BUSINESS

China’s Homegrown Antiviral Covid Pill Included in National Subsidy Program

China approved Genuine Biotech’s Azvudine for adults with normal Covid symptoms under an emergency use authorization in July 2022.
China approved Genuine Biotech’s Azvudine for adults with normal Covid symptoms under an emergency use authorization in July 2022.

China’s homegrown Covid antiviral pill was included in the nation’s medical subsidy program, health authorities said, after pricing talks broke down with Pfizer Inc. to cover its more expensive Paxlovid.

Azvudine developed by Henan-based Genuine Biotech will be priced at 11.58 yuan ($1.71) per pill, and a box of 35 pills will be 175 yuan, compared with 1,890 yuan ($279) to 2,300 yuan for a five-day course of 30 Paxlovid pills, according to the National Health Commission.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST